Tarsus Pharmaceuticals heads into its August 12 earnings release carrying a 14% gain on the week, a short base that has been quietly building for a month, and an options market that has just turned meaningfully less defensive.
The most striking setup this week is the divergence between price momentum and short positioning. TARS has gained 19% over the past month, closing at $69.46 on August 11 — yet short interest has risen 19% in the same period, reaching 14.2% of the free float at roughly 6.04 million shares. That is a meaningful short position for a commercial-stage pharma name, and those shorts are now carrying losses from a stock that has moved sharply against them. The official FINRA settlement figure puts days-to-cover at 6.6, meaning a determined squeeze would take the better part of two weeks to unwind. Despite the elevated short load, the borrow market is far from stressed: availability is running at 481%, meaning there are nearly five shares available to borrow for every one already lent out. Cost to borrow has ticked up 15% this week to 0.60%, but that is still a low absolute rate — this is not a name where shorts are being punished by the lending market itself.
Options positioning has shifted noticeably in the bulls' favour. The put/call ratio has dropped to 1.48, now more than one standard deviation its 20-day average of 1.89. A month ago the ratio was sitting above 2.0 for much of July; this week's drop is the sharpest reset in that window. The 52-week low on the PCR is zero, so the current reading is not at an extreme — but the directional move is clear. Traders who were heavily biased toward puts have reduced that hedge into the print.
The Street is uniformly constructive. Every visible analyst rating is a Buy or Outperform. Oppenheimer lifted its target to $100 from $97 this morning, post-August 12 open. The consensus mean target is $94.86, implying roughly 37% upside from Tuesday's close — though context matters here, since the stock's own momentum has been closing that gap rapidly. The bull case centres on continued XDEMVY revenue growth (full-year guidance of $670-$700M in net sales) and Phase 2 pipeline readouts for ocular rosacea and Lyme disease treatments. The bear case is narrower: it rests on pipeline execution risk and the possibility that XDEMVY's Demodex blepharitis franchise hits a ceiling before market expectations are met. The EPS surprise factor score ranks in the 91st percentile, suggesting the company has a strong recent track record of beating estimates — a relevant data point given tonight's release.
Institutional ownership adds a layer of support. BlackRock recently added 303,525 shares and now holds 8.8% of the company. Vanguard Capital Management established an entirely new position of 2.03 million shares as of June 30. Geode and State Street both added incrementally through July. Against that, insider activity from June shows the CEO, CFO, and several directors all sold shares in the $61-$63 range — all below the current price. Those sales look routine given the accompanying award grants, but the CEO sold nearly 10,000 shares across two transactions. Net insider flow over 90 days was positive in share terms, but the June cluster of sells from the top of the house is worth noting context.
The one prior earnings reaction in the history available is instructive: the August 6 print produced a 5.7% next-day gain. Before that, a June 25 report brought a 6.2% decline. The stock goes into tonight's report up 14% on the week, with shorts sitting on growing unrealised losses and options traders reducing downside hedges — the setup makes the magnitude and direction of any post-print move the immediate number to watch.
See the live data behind this article on ORTEX.
Open TARS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
